ENANTA PHARMACEUTICALS INC
ENTANASDAQTrading Snapshot
- Day Range
- $13.44 – $13.77
- 52-Week Range
- $6.60 – $17.15
- Volume
- $3.97B
- Avg Volume
- $5.12B
- Shares Outstanding
- 29.1M
- Next Earnings
- Aug 31, 2026
Fundamentals Snapshot
- Annual Revenue
- $65M
- Last Q Revenue
- $14M
- P/E Ratio
- -5.3
- P/S Ratio
- 6.0x
- EPS (TTM)
- $-2.17
- Dividend Yield
- 0.00%
Why Investors Own ENTA
- ✓High-growth profile — revenue up +40.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 54% gross margin and 8% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ENANTA PHARMACEUTICALS INC
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.